Diagnostic Utility of Immunohistochemical Expression of HE4 in Epithelial Ovarian Neoplasm: A Cross-sectional Prospective Study


Background: Ovarian cancer has a significant mortality rate due to late diagnosis. Case-specific management can be improved with early and precise diagnosis. Among all gynaecological cancers, ovarian carcinoma has the greatest fatality rate. HE4 (human epididymis protein 4) is a novel biomarker for ovarian cancer diagnosis that has been shown to be overexpressed in ovarian cancer cells.

The study’s goals and objectives were to assess the immunohistochemistry expression of HE4 in diverse epithelial ovarian neoplasms.

Material and Methods: From December 2016 to January 2019, our institution conducted a cross-sectional, prospective, single-institution study in the department of Pathology in partnership with the department of Gynaecology and Obstetrics. This study included a total of 71 patients.

The most prevalent epithelial tumour was serous tumour, followed by mucinous tumour. High-grade serous carcinoma and malignant endometrioid tumours had the highest percentage of HE4 expression. The majority of benign serous and mucinous tumours have a negative expression. We discovered a statistically significant link between HE4 expression and several epithelial ovarian tumour types (p=0.000).

Conclusions: HE4 was found to be strongly expressed in malignant ovarian tumours, particularly serous and endometrioid carcinoma, and could be exploited as a biomarker for ovarian cancer. Its predictive usefulness is also supported by its expression in high-grade ovarian serous carcinoma.

Author(S) Details

Begum Afrin Nahar
Department of Pathology, IPGME&R, Kolkata, India.

Rama Saha
Department of Pathology, IPGME&R, Kolkata, India.

Chhanda Das
Department of Pathology, IPGME&R, Kolkata, India.

Gourishankar Kamilya
Department of Obstetrics and Gynaecology, IPGME&R, Kolkata, India.

View Book:- https://stm.bookpi.org/NFMMR-V11/article/view/3694

Leave A Comment